InvestorsHub Logo
Followers 1
Posts 114
Boards Moderated 0
Alias Born 12/26/2017

Re: mikeslife post# 27830

Wednesday, 07/24/2019 5:25:08 PM

Wednesday, July 24, 2019 5:25:08 PM

Post# of 34624
Look at IOVA, 10% CRs in melanoma and cervical. 3.2B valuation. Give me another CR in group A at some point and I'll make the case we should have a MC at or greater than IOVA. Why? because the scalability is much greater and the opportunity for combination treatment is much greater. We will be able to treat many more cancer types and will not be restricted by neoantigens and tumor mutational burden.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News